Depemokimab has already shown its potential as a therapy for severe asthma in two other phase 3 trials – SWIFT-1 and SWIFT-2 ...

In true form, BIO-Europe will mark its 30th anniversary in Stockholm, Sweden, from November 4-6, 2024. The Nordic region ...

Now, the FDA has added three new products to its list of medicines in short supply as a result of the plant being taken ...

The US regulator has said that compounders can continue to trade in tirzepatide products while it undertakes a review to ...

The once-weekly injectable joins one-shot haemophilia B gene therapy Beqvez (fidanacogene elaparvovec) in Pfizer’s portfolio, ...

Sanofi has bolstered the case for its oral BTK inhibitor tolebrutinib as a treatment for multiple sclerosis (MS), due to be filed for approval in the latter half of this year, with new data in a ...

Premiere healthcare innovation event Frontiers Health is just under a month away. In less than 30 days, health innovators and thought leaders will convene in Berlin for two days of thoughtful ...

Novartis has another phase 3 trial win in its quiver for targeted factor B inhibitor iptacopan, building the case for the drug as a new oral therapy for diseases caused by disorders of the ...

According to the latest Center for Information and Study on Clinical Research Participation (CISCRP) report, “having to travel to the study clinic” is patients’ top-cited participation ...

Apple has the FDA authorisation it needs to bring its software for detecting sleep apnoea to the Apple Watch, coinciding with the launch of its new operating system for the wearable. The Breathing ...

Women with HER2-positive breast cancer can be treated with AstraZeneca and Daiichi Sankyo's Enhertu, regardless of whether their cancer has spread to the brain, according to a new study.

As Ozempic and other GLP-1 drugs explode in popularity, driven by their off-label use for rapid weight loss and viral social media trends, the pharmaceutical industry faces unprecedented challenges.